Application of pediococcus acidilactici PA153 in preparation of probiotic agent for relieving broiler enteritis

The combination of probiotics of PA153 and Bacillus coagulans BC66 in broiler was solved to relieve the problem of enteritis in broiler, significantly slowing the occurrence of enteritis, repairing intestinal morphology, improving growth performance, and achieving safe and efficient anti-Salmonella infection effect .

CN119060898APending Publication Date: 2024-12-03漯河微康农业生物科技有限公司
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411307120.6
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-09-19
Publication Date
2024-12-03

AI Technical Summary

Technical Problem

The prior art is difficult to effectively alleviate enteritis caused by salmonella in broilers, and conventional antibiotics are difficult to enter the intestine and can easily lead to imbalance in the intestinal flora.

Method used

The combination of probiotic agents of PA153 and Bacillus coagulans BC66 were used to significantly slow down or inhibit the occurrence of enteritis, repair the intestinal morphology and promote growth performance by intervening and repairing the intestinal tract of broiler after Salmonella infection.

Benefits of technology

It significantly slows down or inhibits enteritis caused by Salmonella, repairs intestinal mucosa, improves the growth performance of broilers, and is not easy to develop resistance, and has high product safety.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0005049568980000071
    Figure BDA0005049568980000071
  • Figure BDA0005049568980000081
    Figure BDA0005049568980000081
  • Figure BDA0005049568980000091
    Figure BDA0005049568980000091
Patent Text Reader

Abstract

The invention relates to an application of pediococcus acidilactici PA153 in preparation of a probiotic agent for relieving enteritis of broilers. The pediococcus acidilactici PA153 is a pediococcus acidilactici PA153 strain of which the preservation number is CCTCC (China Center for Type Culture Collection) NO: M 2023230, and the pediococcus acidilactici PA153 strain of which the preservation number is CCTCC NO: M 2023230. The brand new application of the pediococcus acidilactici PA153 strain is developed, that is, the pediococcus acidilactici PA153 strain is used for relieving the broiler enteritis symptom caused by salmonella, tests prove that the broiler infected by salmonella and intervened by the PA153 strain can obviously relieve or inhibit enteritis, the negative influence of the growth performance caused by salmonella infection is relieved, and the application of the pediococcus acidilactici PA153 strain to the broiler enteritis is promoted. The PA153 strain can repair the damage of the salmonella to the intestinal morphology, and has a repairing effect on the intestinal mucosa of the broiler chicken infected by the salmonella.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of probiotics and relates to application of Pediococcus acidilactici PA153 in preparing a probiotic agent for alleviating broiler enteritis. Background Art

[0002] Salmonella is a conditional pathogen widely found in nature, and is also a common pathogen that threatens the healthy development of the poultry farming industry. In the current large-scale farming, whether it is broilers, laying hens, or poultry products, there is a risk of Salmonella. Salmonella enters the digestive tract of poultry through feed, invades the digestive system, causes intestinal infection of poultry, and leads to diseases such as diarrhea, which further causes poultry products to carry Salmonella and affect human health. Chickens of different ages will show different clinical characteristics after being infected with Salmonellosis. The younger the chicken, the more severe the symptoms and the higher the mortality rate.

[0003] Conventional antibiotics are easily absorbed into the blood but difficult to enter the intestines to take effect, and are often ineffective against Salmonella that invades the intestines. Antibiotics that are not easily absorbed into the blood often kill all intestinal microorganisms when they enter the intestines, causing an imbalance in intestinal flora and affecting the intestinal health of poultry.

[0004] Some lactic acid Pediococcus have been reported to have the functions of treating constipation, diarrhea, enhancing immune function, maintaining intestinal microecological balance and regulating gastrointestinal flora. Gene sequencing shows that lactic acid Pediococcus has no pathogenic genes and does not produce drug resistance. It is a green and safe feed additive strain. At present, there are few microbial strategies to alleviate enteritis caused by Salmonella in broilers, so it is very necessary to develop more strategies to resist Salmonella infection and alleviate enteritis in broilers. Summary of the invention

[0005] In view of the deficiencies of the prior art, the object of the present invention is to provide a new use of Pediococcus acidilactici PA153, namely, use of Pediococcus acidilactici PA153 in the preparation of a probiotic for alleviating broiler enteritis.

[0006] In order to achieve the purpose of the invention, the present invention adopts the following technical solutions:

[0007] In a first aspect, the present invention provides the use of Pediococcus acidilactici PA153 in the preparation of a probiotic for alleviating broiler enteritis;

[0008] The Pediococcus acidilactici PA153 is a Pediococcus acidilactici PA153 strain with a preservation number of CCTCC NO: M 2023230.

[0009] The present invention develops a new use of the Pediococcus acidilactici PA153 strain, which is to use it to alleviate the symptoms of broiler enteritis caused by Salmonella. Experiments have shown that broilers infected with Salmonella with the PA153 strain intervention can significantly slow down or inhibit the occurrence of enteritis, alleviate the negative impact of growth performance caused by the Salmonella infection, and the PA153 strain can repair the damage to the intestinal morphology caused by Salmonella, and has a repairing effect on the intestinal mucosa of broiler chickens infected with Salmonella.

[0010] Preferably, the dosage form of the probiotic includes solution, lyophilized powder, tablet or granule.

[0011] Preferably, the number of viable bacteria in the probiotic is not less than 1×10 9 CFU / mL or 1×10 9 CFU / g, for example 1×10 9 CFU / g (CFU / mL), 2×10 9 CFU / g (CFU / mL), 5×10 9 CFU / g (CFU / mL), 8×10 9 CFU / g (CFU / mL), 1×10 10 CFU / g (CFU / mL), 5×10 10 CFU / g (CFU / mL), 1×10 11 CFU / g (CFU / mL), 1×10 12 CFU / g (CFU / mL), 1×10 13 CFU / g (CFU / mL), etc. Other specific point values ​​within this numerical range can be selected and will not be described here one by one.

[0012] Preferably, the strains in the probiotics further include Bacillus coagulans BC66 strain with a deposit number of CGMCC No.21879.

[0013] The above-mentioned PA153 strain can not only be used alone to alleviate broiler enteritis, but can also be combined with the BC66 strain to alleviate broiler enteritis.

[0014] The present invention also develops a new probiotic compounding method and a new strategy for alleviating enteritis in broilers caused by Salmonella, that is, Bacillus coagulans BC66 strain and Pediococcus acidilactici PA153 strain are compounded and used together, and it is found that the two can cooperate with each other and promote each other, and synergize in the effects of slowing down or inhibiting the occurrence of enteritis, repairing the damage of intestinal morphology by Salmonella, and promoting the growth performance of broilers. In the case of using the same amount of bacteria, compared with the intervention method of a single BC66 strain or a single PA153 strain, the compounding of the two bacteria significantly improves the effects of slowing down or inhibiting the occurrence of enteritis, repairing the damage of intestinal morphology by Salmonella, and promoting the growth performance of broilers. Therefore, the two probiotics are used to prepare a probiotic agent for alleviating enteritis in broilers, which has a good prospect. At the same time, the above two bacteria are both probiotics, and the product is highly safe and not easy to produce resistance.

[0015] Preferably, the ratio of the number of viable cells of the PA153 strain to that of the BC66 strain is (2-5):1, for example 2:1, 5:2, 3:1, 7:2, 4:1, 9:2, 5:1, etc. Other specific point values ​​within this numerical range can be selected and will not be described here one by one.

[0016] Based on the potential synergistic relationship between the above two strains, when they meet the above-mentioned specific ratio of live bacteria count, they are more effective in slowing down or inhibiting the occurrence of enteritis, repairing the damage of Salmonella to intestinal morphology, and promoting the growth performance of broilers.

[0017] Preferably, the probiotic is in the form of a solution, which is prepared by a preparation method comprising the following steps:

[0018] The required strains are inoculated into culture medium respectively for activation and fermentation culture in sequence to obtain fermentation broth; the fermentation broth is centrifuged and resuspended to obtain bacterial suspension; the bacterial suspension is mixed according to a ratio to obtain the product.

[0019] Preferably, the probiotic is in the form of a freeze-dried powder, which is prepared by a preparation method comprising the following steps:

[0020] The required strains are inoculated into culture medium respectively for activation and fermentation culture in sequence to obtain fermentation liquid; the fermentation liquid is centrifuged respectively, mixed with freeze-drying protective agent and then freeze-dried to obtain bacterial powder; the bacterial powder is mixed according to the ratio to obtain.

[0021] In a second aspect, the present invention provides the use of Pediococcus acidilactici PA153 in the preparation of products for resisting Salmonella infection;

[0022] The Pediococcus acidilactici PA153 is a Pediococcus acidilactici PA153 strain with a preservation number of CCTCC NO: M 2023230.

[0023] The present invention also develops another new use of the Pediococcus acidilactici PA153 strain, which is to use it to prepare products that resist Salmonella infection. Experiments have shown that the PA153 strain has an inhibitory effect of 2×10 8 CFU / g concentration of Salmonella (concentration of 5×10 4 CFU / mL) reached a diameter of 15.7 mm.

[0024] In a third aspect, the present invention provides a probiotic for alleviating enteritis in broiler chickens, wherein the strains in the probiotic are composed of Pediococcus acidilactici PA153 strain with a preservation number of CCTCC NO:M 2023230 and Bacillus coagulans BC66 strain with a preservation number of CGMCC No.21879; the ratio of the number of live bacteria of the PA153 strain to that of the BC66 strain is (2-5):1.

[0025] The present invention also develops a new composite probiotic agent, namely, Bacilluscoagulans BC66 strain and Pediococcus acidilactici PA153 strain are compounded and used in combination at a ratio of viable bacteria count (2-5):1. It is found that the two can cooperate with each other and promote each other, and synergistically enhance the effects in slowing down or inhibiting the occurrence of enteritis, repairing the damage to intestinal morphology caused by Salmonella, and promoting the growth performance of broilers.

[0026] The ratio of the number of viable bacteria of the PA153 strain to the BC66 strain is, for example, 2:1, 5:2, 3:1, 7:2, 4:1, 9:2, 5:1, etc. Other specific point values ​​within this numerical range can be selected, and they will not be listed here one by one.

[0027] Preferably, the dosage form of the probiotic includes solution, lyophilized powder, tablet or granule.

[0028] The number of viable bacteria in the probiotic is not less than 1×10 9 CFU / mL or 1×10 9 CFU / g, for example 1×10 9 CFU / g (CFU / mL), 2×10 9 CFU / g (CFU / mL), 5×10 9 CFU / g (CFU / mL), 8×109 CFU / g (CFU / mL), 1×10 10 CFU / g (CFU / mL), 5×10 10 CFU / g (CFU / mL), 1×10 11 CFU / g (CFU / mL), 1×10 12 CFU / g (CFU / mL), 1×10 13 CFU / g (CFU / mL), etc. Other specific point values ​​within this numerical range can be selected and will not be described here one by one.

[0029] Compared with the prior art, the present invention has the following beneficial effects:

[0030] The present invention develops a new use of the Pediococcus acidilactici PA153 strain, which is to use it to alleviate the symptoms of broiler enteritis caused by Salmonella. Experiments have shown that broilers infected with Salmonella with the PA153 strain intervention can significantly slow down or inhibit the occurrence of enteritis, alleviate the negative impact of growth performance caused by the Salmonella infection, and the PA153 strain can repair the damage to the intestinal morphology caused by Salmonella, and has a repairing effect on the intestinal mucosa of broiler chickens infected with Salmonella.

[0031] At the same time, a new probiotic compound method and a new strategy to alleviate broiler enteritis caused by Salmonella have been developed, that is, the Bacillus coagulans BC66 strain and the Pediococcus acidilactici PA153 strain are compounded and used together. It was found that the two can cooperate and promote each other, and synergistically enhance the effects in slowing down or inhibiting the occurrence of enteritis, repairing the damage to intestinal morphology caused by Salmonella, and promoting the growth performance of broilers.

[0032] The PA153 strain involved in the present invention is classified and named Pediococcus acidilactici PA153, and the depositor is Wuhan University, Wuhan, China. The deposit time is March 2, 2023. The deposit number is CCTCC NO: M 2023230, and the address is No. 3, Yard 1, Beichen West Road, Chaoyang District, Beijing.

[0033] The BC66 strain involved in the present invention is classified and named Bacillus coagulans. The preservation unit is the General Microbiology Center of China Microorganism Culture Collection Administration. The preservation time is March 8, 2021. The preservation number is CGMCC No.21879. The address is: No. 3, Yard 1, Beichen West Road, Chaoyang District, Beijing. DETAILED DESCRIPTION

[0034] In order to further explain the technical means and effects adopted by the present invention, the technical solution of the present invention is further described below in conjunction with the preferred embodiments of the present invention, but the present invention is not limited to the scope of the embodiments.

[0035] The PA153 strain involved in the following examples is classified and named Pediococcus acidilactici PA153, the preservation time is March 2, 2023, and the preservation number is CCTCC NO: M 2023230.

[0036] The BC66 strain involved in the following examples is classified and named Bacillus coagulans, deposited on March 8, 2021, and has a deposit number of CGMCC No.21879.

[0037] The preparation method of the PA153 or BC66 bacterial suspension involved in the following experiment is as follows: the desired strain is inoculated into MRS liquid culture medium, cultured at 37°C for 18 hours for activation, and activated twice in succession to obtain an activated solution; the activated solution is inoculated into MRS liquid culture medium at an inoculum amount of 3% (v / v), and cultured at 37°C for 24 hours to obtain a bacterial solution; the bacterial solution is centrifuged at 4°C and 4000 rpm for 5 minutes, filtered to obtain bacterial bodies, and the bacterial bodies are resuspended in physiological saline.

[0038] MRS medium: peptone 10g / L, beef extract 10g / L, glucose 20g / L, sodium acetate 2g / L, yeast powder 5g / L, diammonium hydrogen citrate 2g / L, K2PO4·3H2O 2.6g / L, MgSO4·7H2O 0.1g / L, MnSO4 0.05g / L, Tween 801mL / L, cysteine ​​hydrochloride 0.5g / L.

[0039] Example 1

[0040] Evaluation of the inhibitory effect on Salmonella:

[0041] (1) The pathogenic bacteria Salmonella were isolated from the intestines of broilers in a chicken farm in Henan Province. After cultivation, a single colony was retained and inoculated into 5 mL LB medium (1% tryptone, 0.5% yeast extract, 1% NaCl, pH 7.2)) and cultured at 37°C and 180 r / min for 12 h. The activated bacterial solution was inoculated into LB medium at a ratio of 1:50 for a second time and activated for 3 h until the logarithmic growth phase. The OD600 absorbance of the bacterial solution was measured according to OD600 = 6 × 10 8 The concentration of Salmonella was calculated using the CFU / mL formula. Salmonella was diluted to 5×10 6 CFU / mL.

[0042] (2) Using the Oxford cup method, add the Salmonella solution to the MRS medium at a ratio of 1:100 and mix thoroughly. Pour the mixture into a culture dish to solidify. Place the Oxford cup in the culture dish and gently pressurize it so that it is in contact with the culture dish without any gaps. Inject 200 μL of 0.5×10 8 CFU / g, 1×10 8 CFU / g, 2×10 8 The PA153 bacterial suspension with a CFU / g was cultured at 37°C for 24 hours and the diameter of the inhibition zone was measured. The results are shown in Table 1.

[0043] Table 1

[0044] concentration Diameter of inhibition zone (mm) <![CDATA[0.5×10 8 CFU / g]]> 13.4 <![CDATA[1×10 8 CFU / g]]> 14.8 <![CDATA[2×10 8 CFU / g]]> 15.7

[0045] It can be seen from the data in Table 1 that the strain Lactobacillus PA153 has an excellent anti-Salmonella effect.

[0046] Example 2

[0047] Impact on Salmonella infection in broiler chickens:

[0048] (1) Experimental animals and grouping:

[0049] A total of 160 one-day-old white-feathered broilers with good health and similar body weight (42±2g) were randomly divided into 8 groups, with 2 independent replicates in each group and 10 chicks in each replicate. The 8 groups were blank control group, probiotic control group, model group, PA153 intervention group, BC66 intervention group, PA153+BC66 intervention group 1, PA153+BC66 intervention group 2, and ATCC8042+ATCC7050 intervention group. The experiment lasted for 7 days.

[0050] (2) Intervention methods:

[0051] (S1) The blank control group was fed a normal basal diet (the diet composition and nutrient level are shown in the table below) from day 1 and had free access to water until day 7;

[0052]

[0053]

[0054] (S2) The probiotic control group was fed with a normal basal diet and drinking water, and was gavaged daily for 10 days from day 1 to day 7. 9 CFU of PA153 bacterial suspension and BC66 bacterial suspension (ratio of viable count was 2:1);

[0055] (S3) The model group was fed with a normal basal diet and drinking water, and was orally gavaged once on day 3 of age with 200 μL of 1×10 9 CFU Salmonella bacterial suspension;

[0056] (S4) The PA153 intervention group was fed with a normal basal diet and drinking water, and gavage was performed for 10 min every day from day 1 to day 7. 9 PA153 suspension containing 1×10 CFU was orally gavaged once at 3 days old. 200 μL of suspension contained 1×10 9 CFU Salmonella bacterial suspension;

[0057] (S5) The BC66 intervention group was fed with a normal basal diet and drinking water, and gavage was performed for 10 min every day from day 1 to day 7. 9 CFU of BC66 suspension was orally administered once at 3 days old, 200 μL containing 1×10 9 CFU Salmonella bacterial suspension;

[0058] (S6) PA153+BC66 intervention group 1 was fed with a normal basal diet and drinking water, and gavage was performed daily for 10 days from day 1 to day 7. 9 CFU PA153 and BC66 suspensions (ratio of viable bacteria count was 2:1) were orally administered once at 3 days of age with 200 μL containing 1×10 9 CFU Salmonella bacterial suspension;

[0059] (S7) PA153+BC66 intervention group 2 was fed with a normal basal diet and drinking water, and gavage was performed daily for 10 days from day 1 to day 7. 9 CFU PA153 and BC66 suspensions (ratio of viable bacteria count was 5:1) were orally administered once at 3 days of age with 200 μL containing 1×10 9 CFU Salmonella bacterial suspension;

[0060] (S8) The ATCC8042+ATCC7050 intervention group was fed with a normal basal diet and drinking water, and gavage was performed daily for 10 days from day 1 to day 7. 9 The mice were orally gavaged once at 3 days old with 200 μL of a suspension of 1×10 CFU of commercially available Pediococcus acidilactici ATCC8042 and a suspension of commercially available Bacillus coagulans ATCC7050 (the ratio of viable count was 5:1). 9 CFU Salmonella bacterial suspension;

[0061] (3)Indicator analysis:

[0062] (3.1) Record the number of dead chickens every day, and calculate the survival rate (%) after the end of the experiment; record the weight and feed consumption of the chickens every day, calculate the daily weight gain (g / day) and daily feed intake (g / day), calculate the feed-to-meat ratio, and calculate the weight (g) after the experiment. The results are shown in Table 2.

[0063] Table 2

[0064]

[0065] It can be seen from the data in Table 2 that compared with the model group, intervention with PA153 strain or combined intervention with PA153 strain and BC66 strain can effectively alleviate the harm of Salmonella to broiler chickens and improve the growth performance of broiler chickens, and the effect of the combined intervention group is better.

[0066] (3.2) After the experiment, blood was randomly collected from 10 broilers in each group, and serum was obtained. The D-lactic acid (D-LA) content and diamine oxidase (DAO) activity in the serum were determined using a biochemical kit method. The kit was purchased from Beijing Solebow Technology Co., Ltd. The results are shown in Table 3.

[0067] Table 3

[0068] Group D-Lactic acid (μg / L) Diamine oxidase (pg / mL) Blank control group 1240.4 312.3 Probiotic control group 744.3 256.1 Model Group 1994.6 854.7 PA153 intervention group 1180.4 436.7 BC66 intervention group 1310.2 476.4 PA153+BC66 intervention group 1 1010.3 422.2 PA153+BC66 intervention group 2 984.2 376.1 ATCC8042+ATCC7050 intervention group 1290.1 625.2

[0069] The permeability of the intestinal mucosa can indirectly reflect the intestinal mucosal barrier function. Under healthy conditions, substances such as DAO and D-LA will not appear in the blood of animals, but as intestinal permeability increases, these substances accumulate in the blood, so they are often used to reflect the integrity of the intestinal barrier. As shown in Table 3, compared with the model group, after intervention with the PA153 strain or combined intervention with the PA153 strain and the BC66 strain, the intestinal mucosa of broilers infected with Salmonella showed signs of recovery, and the combined intervention group had a better effect.

[0070] (3.3) After the experiment, 10 broilers in each group were randomly killed and dissected to obtain intestinal tissue. The fixed intestinal tissue was embedded in paraffin and dehydrated, and then stained with hematoxylin and eosin to prepare tissue sections. The villus height and crypt depth were observed and measured under a biological microscope. The villus height was measured from the tip of the villus to the crypt opening, and the crypt depth was measured from the bottom of the crypt to the crypt opening. Then the average values ​​of the villus height and crypt depth of each section were calculated. The results are shown in Table 4.

[0071] Table 4

[0072] Group Villus height (μm) Crypt depth (μm) Blank control group 709.8 135 Probiotic control group 811.9 120 Model Group 485.4 162 PA153 intervention group 620.5 141 BC66 intervention group 606.3 148 PA153+BC66 intervention group 1 649.2 134 PA153+BC66 intervention group 2 654.7 131 ATCC8042+ATCC7050 intervention group 611.6 152

[0073] It can be seen from the data in Table 4 that compared with the model group, after intervention with PA153 strain or combined intervention with PA153 strain and BC66 strain, the intestinal villus height and crypt depth of the intestinal tissue of broiler chickens were significantly improved, indicating that the probiotics involved in the present invention can repair the damage to the intestinal morphology of broiler chickens caused by Salmonella and alleviate the symptoms of enteritis.

[0074] The applicant declares that the present invention illustrates the technical solution of the present invention through the above-mentioned embodiments, but the present invention is not limited to the above-mentioned embodiments, that is, it does not mean that the present invention must rely on the above-mentioned embodiments to be implemented. Those skilled in the art should understand that any improvement of the present invention, equivalent replacement of various raw materials of the product of the present invention, addition of auxiliary components, selection of specific methods, etc., all fall within the protection scope and disclosure scope of the present invention.

[0075] The preferred embodiments of the present invention are described in detail above. However, the present invention is not limited to the specific details in the above embodiments. Within the technical concept of the present invention, a variety of simple modifications can be made to the technical solution of the present invention, and these simple modifications all belong to the protection scope of the present invention.

[0076] It should also be noted that the various specific technical features described in the above specific embodiments can be combined in any suitable manner without contradiction. In order to avoid unnecessary repetition, the present invention will not further describe various possible combinations.

Claims

1. Application of Pediococcus acidilactici PA153 in the preparation of probiotics for alleviating enteritis in broiler chickens; The Pediococcus acidilactici PA153 is a Pediococcus acidilactici PA153 strain with a preservation number of CCTCC NO: M 2023230.

2. The use according to claim 1, It is characterized in that The dosage form of the probiotics includes solution, lyophilized powder, tablet or granule.

3. The use according to claim 1, It is characterized in that The number of viable bacteria in the probiotic is not less than 1×10 9 CFU / mL or 1×10 9 CFU / g.

4. The use according to claim 1, It is characterized in that The strains in the probiotics also include Bacillus coagulans BC66 strain with a deposit number of CGMCC No.21879.

5. The use according to claim 4, It is characterized in that The ratio of the number of viable bacteria of the PA153 strain to that of the BC66 strain is (2-5):

1.

6. The use according to claim 2, It is characterized in that The dosage form of the probiotic is a solution, which is prepared by a preparation method comprising the following steps: The required strains are inoculated into culture medium respectively for activation and fermentation culture in sequence to obtain fermentation broth; the fermentation broth is centrifuged and resuspended to obtain bacterial suspension; the bacterial suspension is mixed according to a ratio to obtain the product.

7. The use according to claim 2, It is characterized in that The dosage form of the probiotic is a freeze-dried powder, which is prepared by a preparation method comprising the following steps: The required strains are inoculated into culture medium respectively for activation and fermentation culture in sequence to obtain fermentation liquid; the fermentation liquid is centrifuged respectively, mixed with freeze-drying protective agent and then freeze-dried to obtain bacterial powder; the bacterial powder is mixed according to the ratio to obtain.

8. Application of Pediococcus acidilactici PA153 in the preparation of products against Salmonella infection; The Pediococcus acidilactici PA153 is a Pediococcus acidilactici PA153 strain with a preservation number of CCTCC NO: M 2023230.

9. A probiotic for relieving enteritis in broiler chickens. It is characterized in that The strains in the probiotics are composed of Pediococcus acidilactici PA153 strain with a preservation number of CCTCC NO: M 2023230 and Bacillus coagulans BC66 strain with a preservation number of CGMCC No.21879; the ratio of the number of live bacteria of the PA153 strain to that of the BC66 strain is (2-5):

1.

10. The probiotic according to claim 9, It is characterized in that The dosage form of the probiotics includes solution, lyophilized powder, tablet or granule; The number of viable bacteria in the probiotic is not less than 1×10 9 CFU / mL or 1×10 9 CFU / g.